Therapy of Waldenström´s macroglobulinaemia in the year 2014
Authors:
Zdeněk Adam; Marta Krejčí; Luděk Pour; Eva Ševčíková
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.
Published in:
Vnitř Lék 2014; 60(2): 139-157
Category:
Review
Overview
Therapy of Waldenström´s macroglobulinaemia (WM) is indicated in patients with clinically relevant symptoms. Therapeutic plasmapheresis should be performed in cases with hyperviscosity. The intensity of chemotherapy should be adjusted to the degree of cytopenia. Monotherapy with rituximab is recommended in cases with severe cytopenia, also combination of rituximab with dexamethasone should be possible. Patients with symptomatic WM without severe cytopenia should received a rituximab-containing regimens, optimal variant is combination of rituximab + dexamethasone + alkylation drug (such as cyclophosphamide or bendamustine). Possible treatment combinations are for instance R-CHOP (rituximab, cyclophosphamide, vincristine, and prednisone), R-COP (rituximab, cyclophosphamide, and prednisone), or RCD (rituximab, cyclophosphamide, and dexamethasone). The choice of regimen in individual patients will take into consideration performance status, clinical features including renal function, comorbidities and potential candidacy for stem cell transplantation.Chlorambucil and rituximab is possible treatment options for older patients. The choice of treatment of WM relapse depends on the time of treatment response. Retreatment with primary therapy may be appropriate in patients with duration of treatment response at least 2 years. Other treatment possibilities for WM relapse are regimens containing fludarabine, cladribine or bortezomib. Autologous transplantation of peripheral blood stem cells is feasible therapeutic option for relapsed WM in younger, fitter patients with aggressive chemosensitive disease.
Key words:
bendamustin – bortezomib – rituximab – hyperviscosity – cryoglobulinemia – cold agglutinin disease – monoclonal imunoglobulin related disorders – Waldenström´s macroglobulinaemia
Sources
1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia – a new syndrome? Acta Med Scand 1944; 117 (3–4): 216–247.
2. Wang H, Chen Y, Li F et al. Temporal and geografic variations of Waldenström macroglobulinemia incidence: a large population-based study. Cancer 2012; 118(15): 3793–3800.
3. Vos JM, Minnema MC, Wijermans PW et al. Guidelines for diagnosis, treatment of Waldenström´s macroglobulinaemia. Neth J Med 2013; 71(2): 54–62.
4. Ciccarelli BT, Patterson CJ, Hunter ZR et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 160–163.
5. Treon SP, Tripsas CK, Ciccarelli BT et al. Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leuk 2013; 13(2): 241–243.
6. Hivert B, Caron C, Petit S et al. Clinical and prognostic implications of low level of von Willebrand factor in patients with Waldenström macroglobulinemia. Blood 2012; 120(16): 3214–3221.
7. Adam Z, Šmardová J, Ščudla V. Waldenströmova makroglobulinémie – klinické projevy, diferenciální diagnostika a prognóza nemoci. Vnitr Lek 2007; 53 (12): 1325–1337.
8. Pujani M, Kushwaha S, Sethi N et al. Waldenstrom’s macroglobulinemia presenting with lytic bone lesions: a rare presentation. Blood Res 2013; 48(3): 230–233.
9. Ševčíková S, Novák L, Kubiczková L et al. Molekulární základy Waldenströmovy makroglobulinemie. Klin Onkol 2012; 25(6): 413–420.
10. Pochop P, Hochová I. Retinopatie jako komplikace Waldenströmovy makroglobulinemie. Cesk Slov Oftalmol 2003; 59(1): 23–27.
11. Churý Z, Drbal J, Jedlicková H et al. Erythema exsudativum multiforme s makroglobulinemií. Vnitr Lek 1999; 45(9): 552–554.
12. Tichý M, Hrnčír Z, Matĕja F et al. Paraprotein IgM N-K s vlastnostmi kryoglobulinu. Čas Lék Česk 1971; 110(33): 761–765.
13. Hrnčír Z, Matĕja F. Revmatoidní faktor u mnohočetného myelomu a Waldenströmovy makroglobulinemie. Čas Lék Česk 1966; 105(13): 351–354.
14. Rencová E, Malý J, Bláha M et al. Dynamika změn retiny v průběhu léčby Waldenströmovy makroglobuilnémie. Česk Oftalmol 1993; 49(1): 3–7.
15. Špička I, Cieslar P, Dyr JE et al. Hemostáza u monoklonálních gammopatií. Sb Lek 1991; 93(9–10): 277–286.
16. Ščudla V, Minařík J, Pika T. Light chain deposition disease. Vnitr Lek 2012; 58(1): 38–43.
17. Ščudla V, Herman M, Minařík J et al. Přínos celotělové MR pro diagnostiku monoklonálních gamopatií nejasného významu a mnohočetného myelomu. Vnitr Lek 2011; 57(1): 52–60.
18. Mysliveček M, Bačovský J, Ščudla V et al.18F-FDG PET/CT a 99mTc-MIBI scintigrafie u pacientů s mnohočetným myelomem a monoklonální gamapatií nejistého významu. Klin Onkol 2010; 23(5): 325–331.
19. Adam Z, Pejchalová A, Chlupová G et al. Nemoc chladových aglutininů nereagující na léčbu glukokortikoidy a na léčbu rituximabem. Jaký postup zvolit pro třetí linii léčby? Popis případu a přehled literatury. Vnitr Lek 2013; 59(9): 828–840.
20. Ščudla V, Bačovský J, Indrák K e al. Výsledky léčby a změny v prognóze pacientů s mnohočetným myelomem ve střední a severní Moravě v posledních 40 letech. Vnitr Lek 2002; 48(8): 707–717.
21. Ščudla V. Anémie chronických chorob, standardní postupy při diagnostice a léčbě. Doporučení Hematologické společnosti České lékařské společnosti J. E. Purkyně. Vnitr Lék 2002; 48(5): 422–426.
22. Adam Z, Ščudla V, Krejčí M et al. Léčba Waldenströmovy makroglobulinemie a léčba nemocí způsobených monoklonálním gamaglobulinem. Vnitr Lék 2008; 54(1): 68–83.
23. Banwait R, O’Regan K, Campigotto F et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol 2011; 86(7): 567–572.
24. Tripsas CK, Patterson CJ, Uljon SN et al. Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13(2): 250–252.
25. Salviani C, Guido G, Serriello I et al. Renal involvement in Waldenström’s macroglobulinemia: case report and review of literature. Ren Fail. 2014;36(1):114–8.
26. Gnemmi V, Leleu X, Provot F et al. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. Am J Kidney Dis 2012; 60(3): 487–491.
27. Ramachandran R, Rathi M, Malhotra P. Light chain cast nephropathy in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant 2012; 27(4): 1687–1688.
28. Feringa HH, Ardestani A, Gnanaraj J. Distal renal tubular acidosis in lymphoplasmacytic lymphoma Waldenström’s macroglobulinemia: a case report. Cases J 2009; 2: 7198.
29. Castro H, Valenzuela R, Ruiz P et al. Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenström’s Macroglobulinemia: a case report. Cases J 2008; 1(1): 333.
30. Shaikh A, Habermann TM, Fidler ME et al. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström’s macroglobulinemia. Clin Exp Nephrol 2008; 12(4): 292–295.
31. Morel P, Duhamel A, Gobbi P et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009; 113(18): 4163–4170.
32. Johnson SA, Birchall J, Luckie C et al. Guidelines on management of Waldenström´s macroglobulinemia. Brit J Haematol 2006; 132(6): 683–697.
33. Owen RG, Kyle RA, Stone MJ et al. VI International Workshop on Waldenström macroglobulinemia. Response assessment in Waldenström macroglobulinemia: update from the VI international Worshop. Br J Haematol 2013; 160(2): 171–176.
34. Dimopoulos MA, Kyle RA, Anagnastopoulos A et al. Diagnosis and management of Wadenström´s macroglobulinemia. J Clin Oncol 2005; 23(7): 1564–1577.
35. Björkholm M Treatment options in Waldenström´s macroglobulinemia. Clin Lymphoma 2004; 5(3): 155–162.
36. O´Reilly RA, MacKanzie MR. Primary macroglobulinaemia: remission with adrenal corticosteroid therapy. Arch Intern Med 1967; 44: 889–890.
37. Jane SM, Salem HH. Treatment of resistant Waldenström´s macroglobulinaemia with high dose glucocorticosteroids. Aust NZJ Med 1988; 18(1): 77–78.
38. Kyle RA, Greipp PR, Gertz MA et al. Waldenström´s macroglobulinemia. A prospective study comparing daily with intermittent oral chlorambucil. Brit J Haematol 2000; 108(4): 737–742.
39. Annibali O, Petruci MT, Martini V et al. Treatment of 72 newly diagnosed Waldenström´s macroglobulinemia cases with oral melphalan, cyclophosphamide and prednisone: results and cost analysis. Cancer 2005; 103(3): 582–587.
40. Johnson SA. Waldenström macroglobulinaemia. Rev Clin Exp Hematol 2002; 6(4): 421–334 and discussion 449–450.
41. Gertz MA, Anagostopoulos A, Anderson K et al. Treatment recommendation in Waldström´s macroglobulinaemia. Consensus panel recommendation from the second international workshop on Waldenstöm´s macroglobulinaemia. Semin Oncol 2003; 30(2): 121–126.
42. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Worshop on Waldenström´s macroglobulinaemia. Blood 2006; 107(9): 3442–3446.
43. Hensel M, Villalobos M, Kornacker M et al. Pentostatin/cyclophosphamide with or without rituximab: An effective regimen for patients with Waldenström´s macroglobulinemia/lymphoplasmocytic lymphoma. Clin Lymphoma Myeloma 2005; 6(2): 131–135.
44. Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in Waldenström´s macroglobulinemia: an update of a US Intergroup trial (SW0G S9003). Semin Oncol 2003; 30(2): 220–225.
45. Leblond V, Lévy V, Maloisel F et al. Multicenter randomized ¨comparative trial of fludarabine and the combination of cyclophosphamide doxorubicin prednisone in 92 patients with Waldenström´s macroglobulinaemia in first relapse or with primary refractory disease. Blood 2001; 98(9): 2640–2644.
46. Leblond V, Johnson S, Chevret S et al. Results of a randomised trial comparing chlorambucil versus fludarabine for patients with untreated Waldenström´s macroglobulinemia, marginal zone lymphoma or lymphoplasmocytic lymphoma. J Clin Oncol 2013; 31(3): 301–307.
47. Jacobs A. Cold aglutinin hemolysis responding to fludarabine therapy. Am J Hematol 1996; 53(4): 279–280.
48. Lewandowsky K, Halaburda K, Hellman A et al. Fludarabine therapy in Waldenström´s macroglobulinemia patients treated previously with 2-chlordeoxyadenosine. Leukemia Lymphoma 2002; 43(2): 361–363.
49. Dimopoulos MA, Weber D, Kantarjian H et al. 2Chlordeoxyadenosine therapy of Waldenström´s macroglobuliniaemia previously treated with fludarabine. Ann Oncol 1994; 5(3): 288–289.
50. Leblond V, Ben-Othman T, Deconinck E et al. Activity of fludarabine in previously treated Waldenstöm´s macroglobulinaemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. J Clin Oncol 1998; 16(6): 2060–2064.
51. Dimopoulos MA, Hamilos G, Efstathiou E et al. Treatment of Waldenström´s macroglobulinaemia with combination of fludarabine and cyclophosphamide. Leukemia Lymphoma 2003; 44(6): 993–996.
52. Tamburini JL, Chaleteix V, Cermane JP et al. Fludarabine plus cyclophoshamide in Waldenström´s macroglobulinemia. Results in 49 patients. Leukemie 2005; 19(10): 1831–1834.
53. Tam CS, Wolf MM, Westerman D et al. Fludarabine combination therapy is highly effective in fist line and salvage treatment of patients with Waldenström´s macroglobulinemia. Clin Lymphoma Myeloma 2005; 6(2): 136–139.
54. Tam CS, Wolf M, Prince HM et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent lymphoma. Cancer 2006; 106(11): 2412–2420.
55. Weber DM, Dimopoulos MA, Dalasalle K et al. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenström´s macroglobulinemia. Semin Oncol 2003; 30(2): 243–247.
56. Tedeschi A, Benevolo G, Varettoni M et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström´s macroglobulinemia. An effective but myelosupresive regiment to be offered to patients with advanced disease. Cancer 2012; 118(2): 434–443.
57. Bowcock SJ, Rassam SM, Lim Z et al. High incidence of therapy releated myelodysplasia and acute leukemia in general hematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Brit J Haematol 2006; 134(2): 242–243.
58. Tam CS, Seymour JF, Prince JM. Treatment releated myelodysplasia following fludarabine combinations chemotherapy. Haematologica 2006; 91(11): 1546–1550.
59. Leleu Y, Manning R, Soumerai J et al. Increased incidence of disease transformation and development of MDS/AML in Waldenström´s macroglobulinemia patients treated with nucleoside analogs. Haematologica 2007; Suplementum 2, abstr. WM3.10.
60. Souchet-Compain L, Nguyen S, Choquet S et al. Fludarabine in Waldenstrom’s macroglobulinemia. Expert Rev Hematol 2013; 6(3): 229–237.
61. Souchet-Compain L, Nguyen S, Choquet S et al. Primary therapy of Waldenström macroglobulinemia with nucleoside analogue-based therapy. Clin Lymphoma Myeloma Leuk 2013; 13(2): 227–230.
62. Gertz MA, Rue M, Blood E et al. Multicenter phase II trial of rituximab in Waldenström´s macroglobulinaemia. An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45(10): 2047–2055.
63. Dimopoulos MA, Zervas C, Zomas A. Extended rituximab therapy for previously untreated patients with Waldenstöm´s macroglobulinaemia. Clin Lymphoma 2002; 3(3): 163–166.
64. Treon SP, Emmanoulides C, Kimby E et al. Extended rituximab therapy in Waldenström´s macroglobulinaemia. Ann Oncol 2005; 16(1): 132–138.
65. Ghobrial IR, Fonseca R, Greipp PR et al. Initial imunoglobulin M flare after rituximab therapy in patients diagnosed with Waldenström´s macroglobulinaemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101(11): 2593–2598.
66. Dimopoulos MA, Anagnostopoulos A, Zervas C et al. Predictive factors for response to rituximab in Waldenström macroglobulinemia. Clin Lymphoma 2005; 5(4): 270–272.
67. Treon SP, Hansen M, Branagan AR et al. Polymorphismus in FCgama (CD16) receptor expression are associated with clinical response to rituximab in Waldenström macroglobulinemia. J Clin Oncol 2005; 23(3): 474–481.
68. Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenström´s macroglobulinaemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10(12): 1525–1527.
69. Treon SP, Agus DB, Link B et al. CD20 directed antibody mediated immunotherapy induces response and facilitates hematologic recovery in patients with Waldenström´s macroglobulinaemia. J Immunother 2001; 24(3): 272–279.
70. Weber DM, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports rituximab for Waldenström´s macroglobulinemia. Blood 1999; 94(Suppl 1): abstr 549.
71. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab for patients with newly diagnosed mantle cell lymphoma, imunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18(2): 317–324.
72. Buske C, Hoster E, Dreyling M. German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapywith CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomizedtrial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23(1): 153–156.
73. Dimopoulos MA, Anagnastopoulos A, Kyrtsonis MC et al. Primary treatment of Waldenström´s macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol 2007; 25(22): 3344–3349.
74. Treon SP, Hunter ZR, Branagan AR. CHOP plus rituximab therapy in Waldenström´s macroglobulinemia. Clin Lymphoma 2005; 5(4): 273–277.
75. Ioakimidis L, Patterson CJ, Hunter ZR et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 62–66.
76. Gertz MA. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013; 88(8): 703–711.
77. Weber DM, Thomas S, Wang M et al. Rituximab alone or in combination in the frontline treatment of Waldenström´s macroglobulinemia. Haematologica 2003; 88(Suppl 2): abstr WM2.
78. Treon SP, Wasi P, Emmanoulides CA. Combination therapy with rituximab and fludarabine is highly active in Waldenström´s macroglobulinemia. Blood 2002; 100(Suppl 1): abstr.
79. Tam CS, Wolf M, Prince HM et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent lymphoma. Cancer 2006; 106(11): 2412–2420.
80. Tedeschi A, Miqueleiz AS, Ricci F et al. Fludarabine cyclophosphamide and rituximab an effective regimen characterized by high incidence of delayed responses in Waldenström´s macroglobulinaemia. Haematologica 2007; 92(Suppl 2): abstr 1225.
81. Vargaftig J, Pegourie-Bandelier B, Mahe B et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström´s macroglobulinemia. Results in 25 patients. Haematologica 2007; 92(Suppl 2): abstr. 1226.
82. Thomas SK, Delassale KB, Gavino M et al. 2-CDA cyclophosphamide plus rutuximab for symptomatic WM. Haematologica 2007; 92(Suppl 2): abstr 1227.
83. Laszlo D, Andreola G, Rigacci L et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine as therapy in untreated and relapsed Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 130–132.
84. Treon SP, Hanzis C, Manning RJ et al. Maintenance rituximab is associated with improved clinical outcome in rituximabe naive patients with Waldenström´s macroglobulinemia, who respond to rituximanb containing regimen. Br J Haematol 2011; 154(3): 357–362.
85. Dimopoulos MA, Zomas A, Viniou NA. Treatment of Waldenström macroglobulinemia with thalidomide. J Clin Oncol 2001; 19(16): 3596–3601.
86. Treon SP, Soumerai JD, Branagan AR et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112(12): 4452–4457.
87. Coleman M, Leonard J, Lyons L et al. Treatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003; 30(2): 270–274.
88. Dimopoulos MA, Tsatalas C, Zomas A et al. Treatment of Waldenstrom’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30(2): 265–269.
89. Treon SP, Soumerai JD, Branagan AR et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2009; 15(1): 355–360.
90. Santos DD, Hatjiharissi E, Tournilhac O. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom’s Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006; 6(6): 478–483.
91. Tournilhac O, Santos DD, Xu L et al. Mast cells in Waldneström´s macroglobulinemia support lymphoplasmocytic cell growth trough CD154/CD40 signaling. Ann Oncol 2006; 17(8): 1275–1282.
92. Owen RG, Hillmen P, Rastron AC. CD52 expression inWaldenström´s macroglobulinaemia: Implication for alemtuzumab therapy and response assessment. Clin Lymphoma 2005; 5(4): 278–281.
93. Treon SP, Soumerai JD, Hunter ZR et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118(2): 276–281.
94. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Treatment of relapsed or refractory Waldenström’s macroglobulinemia with bortezomib. Haematologica 2005; 90(12): 1655–1658.
95. Treon SP, Hunter ZR, Matous J et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’smacroglobulinemia: results of WMCTG Trial 03–248. Clin Cancer Res 2007; 13(11): 3320–3325.
96. Chen CI, Kouroukis CT, White D et al. Bortezomib is active in patients with untreated or relapsem Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(12): 1570–1577.
97. Chen C, Kouroukis CT, White D et al. Bortezomib in relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 74–76.
98. Ghobrial IM, Hong F, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28(8): 1422–1428.
99. Treon SP, Ioakimidis L, Soumerai JD et al Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol 2009; 27(23): 3830–3835.
100. Dimopoulos MA, García-Sanz R, Gavriatopoulou M et al. Primary therapy of Waldenstrom’s macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone and rituximab (BDR): long term results of a phase II study of the European Myeloma Network (EMN). Blood 2013; 122(19): 3276–3282.
101. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M et al. Primary therapy of Waldenström´s macroglobulinemia with weakly bortezomib, low dose dexametazon and rituximab: a phase II study of the European Myeloma Network. ASH Annual Meeting Abstracts 2010; abstr 1941.
102. Ghobrial IM, Xie W, Padmanabhan S et al. Phase II trial of weekly bortezomib in combinatin with rituximab in untreated patients with Waldenström´s macroglobulinemia. Am J Hematol 2010; 85(9): 670–674.
103. Marchand T, Tas P, Houot R et al. Cutaneous macroglobulinosis treated with bortezomib and rituximab. Eur J Haematol 2011; 87(1): 98.
104. Agathocleous A, Rohatiner A, Rule S et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol 2010; 151(4): 346–353.
105. Laubach JP, Mitsiades CS, Roccaro AM et al. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma 2009; 50(5): 694–702.
106. Roccaro AM, Sacco A, Leleu X et al. Role of proteasome inhibition in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 94–96.
107. Pascal L, Gay J, Willekens C et al. Bortezomib and Waldenstrom’s macroglobulinemia. Expert Opin Pharmacother 2009; 10(5): 909–916.
108. Dimopoulos MA, Gertz MA, Gastritis E et al. Update on treatment recommendation from the fourht International Workshop on Waldenström´s macroglobulinemia. J Clin Oncol 2009; 27(1): 120–126.
109. Dimopoulos MA, Chen C, Kastritis E et al. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2010; 10(2): 110–117.
110. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström´s macroglobulinemia. Clin Lymphoma Myeloma and Leuk 2013; 13(2): 235–237.
111. O’Connor SR, Rana SK. Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab. Br J Haematol 2013; 161(4): 460.
112. Vidal L, Gafter-Gvili A, Gurion R et al. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012; 9: CD009045. Dostupné z DOI: <http://doi: 0.1002/14651858 .CD009045.pub2>.
113. Knauf WU, Lissitchkov T, Aldaoud A et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012; 159(1): 67–77.
114. Pönisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132(4): 205–212.
115. Treon SP, Hanzis C, Tripsas C et al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 133–135.
116. Rummel MJ, Niederle N, Maschmeyer G et al. Study Group for indolent lymphoma. Bendamustine plus rituximab versus CHOP plus rituximab as first line treatment for patients with indolent and mantle-cell lymphoma: an open-label, multicenter, randomised phase 3 non inferiority-trial. Lancet 2013; 381(9873): 1203–1210.
117. Gueli A, Gottardi D, Hu H et al. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Blood Transfus 2013; 11(2): 311–314.
118. Takemori N, Hirai K, Onodera R et al. Durable remission after splenectomy for Waldenström´s macroglobulinaemia with massive splenomegaly in leukemic phase. Leukem Lymphoma 1997; 26(3–4): 387–393.
119. Gertz MA, Reeder CB, Kyle RA. Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2012; 47(9): 1147–1153.
120. Bachanova V, Burns LJ. Hematopoietic cell transplantation for Waldenström macroglobulinemia. Bone Marrow Transplant 2012; 47(3): 330–336.
121. Kyriakou C, Canals C, Cornelissen JJ. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28(33): 4926–4934.
122. Kyriakou C, Canals C, Sibon D et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28(13): 2227–2232.
123. Garnier A, Robin M, Larosa F et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2010; 95(6): 950–955.
124. Caravita T, Siniscalchi A, Tendas A et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom’s macroglobulinemia. Bone Marrow Transplant 2009; 43(7): 587–588.
125. Gilleece MH, Pearce R, Linch DC et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008; 13(2): 119–127.
126. Einstein R. Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders. J Clin Apheresis 2006; 21(2): 100–104.
127. Clark WF, Rock GA, Buskard N et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131(6): 453–462.
128. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012; 119(10): 2205–2208.
129. Ansell SM, Kyle RA, Reeder CB et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85(9): 824–833.
130. Menke MN, Feke GT, McMeel JW et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 100–103.
131. Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher 2002; 6(1): 45–52.
132. Dimopoulos MA, Gastritis E, Rousou M et al. Rituximab based treatments in Waldenström´s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 59–61.
133. Dimopoulos MA, Gertz MA, Kastritis E et al. Update on the treatment recomendation from the Fourth International Workshop on Waldenström´s macroglobulinemia. J Clin Oncol 2009; 27(1): 120–126.
134. Anderson KC, Alsina M Bensinger W et al. Waldenström macroglobulinemia/lymfoplamocytic lymphoma. Version 2. 2013 J Natl Compr Canc Netw 2012; 10(10): 1211–1219.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2014 Issue 2
Most read in this issue
- MRI compatible cardiac pacemakers and implantable cardioverter defibrillators
- Dynamics of interleukin 6 levels in the patients with cardiogenic and septic shock and in a control group of patients with uncomplicated AMI
- Catheter Related Septic Central Venous Thrombosis of the Superior Vena Cava and Right Atrium
- The place of JAK2 inhibitors in the treatment of myelofibrosis. An amendment to the recommendations for diagnosis and treatment of Ph negative myeloproliferations of the Czech group for Ph- myeloproliferative disorders (CZEMP)